CN113559118B - 亚铁离子在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用 - Google Patents
亚铁离子在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用 Download PDFInfo
- Publication number
- CN113559118B CN113559118B CN202110893972.8A CN202110893972A CN113559118B CN 113559118 B CN113559118 B CN 113559118B CN 202110893972 A CN202110893972 A CN 202110893972A CN 113559118 B CN113559118 B CN 113559118B
- Authority
- CN
- China
- Prior art keywords
- cyhv2
- infection
- ferrous ions
- fecl
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 23
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 title abstract description 17
- 229910001448 ferrous ion Inorganic materials 0.000 title abstract description 17
- 241001487666 Cyprinid herpesvirus Species 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 8
- 241000252233 Cyprinus carpio Species 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229910021577 Iron(II) chloride Inorganic materials 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 18
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 229960002089 ferrous chloride Drugs 0.000 abstract description 3
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 2
- 238000003753 real-time PCR Methods 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 241000251468 Actinopterygii Species 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 9
- 241001609213 Carassius carassius Species 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101100069690 Orgyia pseudotsugata multicapsid polyhedrosis virus GTA gene Proteins 0.000 description 3
- 101000953093 Salmonella phage P22 Uncharacterized 9.0 kDa protein in gp15-gp3 intergenic region Proteins 0.000 description 3
- 101710173665 Uncharacterized 5.8 kDa protein Proteins 0.000 description 3
- 101710172361 Uncharacterized protein ycf17 Proteins 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 101150055367 orf47 gene Proteins 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000252211 Carassius Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 229940116007 ferrous phosphate Drugs 0.000 description 2
- 150000003278 haem Chemical group 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229910000155 iron(II) phosphate Inorganic materials 0.000 description 2
- SDEKDNPYZOERBP-UHFFFAOYSA-H iron(ii) phosphate Chemical compound [Fe+2].[Fe+2].[Fe+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O SDEKDNPYZOERBP-UHFFFAOYSA-H 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007938 immune gene expression Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了亚铁离子在防治鲤疱疹病毒Ⅱ型（cyprinid herpesvirus 2，CyHV2）感染中的应用，实验动物感染模型的建立显示，氯化亚铁能够对鲫鱼CyHV2感染起到显著的保护作用，结合qPCR实验结果发现氯化亚铁处理后病毒相关基因转录水平被显著抑制。因此，含有亚铁离子的化合物能够作为防治CyHV2的药物，并具有使用剂量无毒安全，保护效果佳的优点。
Description
技术领域
本发明属于水产养殖技术领域，具体涉及亚铁离子的医药用途，含有亚铁离子的化合物可用于预防和治疗鲤疱疹病毒Ⅱ型(CyHV2)感染引起的水产动物疾病。
背景技术
铁是生物体内重要的六大微量元素之一，是动植物正常生长和生活的必需元素。在生物体内，铁承担着多种生物学功能。一般地，铁在机体内以Fe2+/3+血红素形式存储，其中+2价亚铁离子的功能表现在许多方面。
亚铁离子作为血红蛋白的重要组成成分，负责携带氧及输送氧，实现红细胞的输氧功能。用于肌肉贮氧的肌红蛋白中均含有一个亚铁血红素，当肌肉运动时，它可以提供或补充血液输氧的不足；另外，亚铁离子能够与细胞内活性酶的代谢产物发生相互作用。细胞色素酶类在体内氧化还原过程中不可或缺，它是完成电子传递的关键角色，并在三羧酸循环过程中催化脱下的氢原子与由血红蛋白运输的氧合成水，以保证代谢。在这一氧化过程中所产生的过氧化氢等有害物质，能够被含铁的触媒所破坏而解毒。造血功能方面，铁影响脱氧核糖核苷酸合成及造血维生素的代谢。机体应对病原体入侵时，细胞内亚铁离子水平的升高能够通过催化氧自由基的形成，激活免疫因子NF-κB启动信号转导，促进局部炎症的产生，唤醒免疫反应，并防止感染的扩散。铁与酶之间的关键作用和其参与的造血功能决定着缺乏铁元素，会引起机体感染程度增加，白细胞功能异常，免疫屏障受损。亚铁离子在机体免疫过程中至关重要，但目前尚未有将外源亚铁离子应用于防治水生动物病毒病的实例。
鲤疱疹病毒Ⅱ型(cyprinid herpesvirus 2,CyHV2)是造成金鱼、鲫鱼等鲤科鱼类病毒性鳃出血症的病原，一旦暴发会引起养殖鱼类大规模死亡。其中尤以鲫作为中国重要的大宗淡水经济鱼类，疱疹病毒的流行每每带来巨大的经济损失。疱疹病毒病因其发病速度快，致死率高的特点，目前已被世界动物卫生组织(OIE)收入须重点检疫申报的疾病名录及我国“国家水生动物疫病监测”名录。目前，针对水生动物病毒病的防治手段十分有限，尽管针对鱼类疱疹病毒病原分离、组织病理观察、转录组分析等方面已开展一些研究，但研究人员尚未找到良好的防治方式。深入了解病原CyHV2，提出行之有效的防治手段是控制病毒暴发，减少经济损失是水产养殖业亟需解决的问题。
发明内容
本发明的目的在于提供含有亚铁离子的化合物在制备防治鲤疱疹病毒Ⅱ型(CyHV2)感染药物中的应用，FeCl2能够显著抑制鱼体免疫器官中病毒相关基因(包括ORF47，ORF48，ORF80)的表达，实验动物存活率模型证实FeCl2对CyHV2感染起到保护作用，含有亚铁离子的化合物能够用于制备防治CyHV2感染的药物。
为了实现上述目的，本发明采用以下技术方案：
含有亚铁离子的化合物在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用：在本发明的具体实施例中，感染CyHV2的鲫鱼在注射FeCl2后，因病毒感染造成的死亡率被显著降低，0.1mg/g FeCl2处理时死亡率为0，进一步检测鱼体中病毒相关基因扩增情况显示，FeCl2处理之后，鱼体免疫器官脾脏、头肾、体肾中病毒相关基因(包括ORF47，ORF48，ORF80)的表达量被显著抑制。同时，上述免疫器官中抗病毒免疫相关基因(包括caRIG-I A/B,caViperinA/B)表达量基本恢复正常水平。
本发明实施例中选取的鲫鱼是CyHV2的重要宿主，因此通过建立鲫鱼感染CyHV2的疾病模型，以及对病毒相关基因表达的检测，可知含有亚铁离子的化合物，如氯化亚铁(FeCl2)、硫酸亚铁(FeSO4)、磷酸亚铁(Fe3H16O16P2)、葡萄糖酸亚铁(C12H22O14Fe·2H2O)等适用于CyHV2感染的防治。含有亚铁离子的化合物作为预防或治疗CyHV2的药物，可以制成注射剂或口服剂，使用剂量低，成分单一，无毒副作用，没有药物残留的风险。
附图说明
图1为注射不同微量元素氯化物对感染CyHV2鲫鱼存活率的影响。
图2为注射FeCl2对感染CyHV2鲫鱼体内病毒基因表达水平的影响。
图3为注射FeCl2对感染CyHV2鲫鱼体内抗病毒免疫相关因子表达水平的影响。
具体实施方式
实施例1：FeCl2对鲫鱼感染CyHV2后致死率的影响
在35cm×23.5cm×36cm的水族箱中进行，每天换水并保持水温在22℃左右。5g左右的健康鲫鱼通过腹腔注射CyHV2病毒悬液建立人工感染模型，对照组腹腔注射病毒悬液250μl/尾与PBS 50μl/尾混合液，实验组使用病毒悬液250μl/尾按照总体积为300μl/尾分别稀释FeCl2溶液(0.12675g/ml)、氯化锰溶液(MnCl2，0.19791g/ml)、氯化铜溶液(CuCl2，0.17048g/ml)、氯化镁溶液(MgCl2，0.09521g/ml)、氯化钙溶液(CaCl2，0.111g/ml)至终浓度0.1mg/g(使用PBS补齐体积)，同时注射感染。感染后每天记录鲫鱼死亡情况，一直统计到15dpi(days post infection)，最终用Mantel-Cox分析鱼体存活率(图1)。该结果表明，对照组鲫鱼感染CyHV2后在第7天存活率为0，注射其余微量元素氯化物实验组鲫鱼全部死亡时间在1dpi至10dpi不等。而注射0.1mg/g FeCl2的鲫鱼未见死亡，存活率提高到100％，可见FeCl2对鲫鱼感染CyHV2有明显的保护效果。
实施例2：FeCl2对感染CyHV2鲫鱼体内病毒基因表达水平的影响
检测感染CyHV2之后的鱼体用0.1mg/g FeCl2处理后，鱼体中病毒相关基因的表达情况。按照实施例1所述方法分别处理对照组和FeCl2-CyHV2混合液组，每组鲫鱼分别腹腔注射300μl混合液，感染6天后用MS-222麻醉(0.1mg/ml)，解剖取脾脏(Spleen)、头肾(Headkidney)与体肾(Kidney)样品，使用TRIzol(Invitrogen)提取组织总RNA，由GoScript逆转录试剂盒(Promega)逆转录得到cDNA。通过qPCR检测病毒相关基因的表达情况(图2)(每组设置5个生物学重复)，结果表明：0.1mg/g FeCl2处理之后，鱼体免疫器官中病毒相关基因(包括ORF47，ORF48，ORF80)的表达显著下降。
实施例3：FeCl2对感染CyHV2鲫鱼抗病毒免疫相关基因表达的影响
进一步检测感染CyHV2之后的鱼体用0.1mg/g FeCl2处理后，抗病毒免疫基因的表达情况。5g左右的健康鲫鱼被分为PBS组，PBS-FeCl2混合液组，FeCl2-CyHV2混合液组和CyHV2病毒悬液组。其中，PBS组注射PBS 300μl/尾；PBS-FeCl2混合液组使用PBS稀释FeCl2溶液至0.1mg/g，总体积为300μl/尾；FeCl2-CyHV2混合液组使用CyHV2病毒悬液稀释FeCl2溶液至0.1mg/g；CyHV2病毒悬液组将CyHV2病毒悬液与FeCl2溶液等量体积的PBS混合；如上所述同时注射感染，感染6天后麻醉解剖取脾脏、头肾及体肾组织提取总RNA逆转录后进行qPCR检测(图3)。结果显示：CyHV2病毒悬液组鲫鱼脾脏、头肾、体肾中抗病毒免疫基因表达显著上调，加入FeCl2处理后相关基因表达基本恢复正常水平。
Claims (1)
1.FeCl2作为唯一活性成分在制备防治鲤疱疹病毒Ⅱ型感染的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110893972.8A CN113559118B (zh) | 2021-08-04 | 2021-08-04 | 亚铁离子在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110893972.8A CN113559118B (zh) | 2021-08-04 | 2021-08-04 | 亚铁离子在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113559118A CN113559118A (zh) | 2021-10-29 |
| CN113559118B true CN113559118B (zh) | 2022-05-03 |
Family
ID=78170427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110893972.8A Active CN113559118B (zh) | 2021-08-04 | 2021-08-04 | 亚铁离子在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113559118B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040537B (zh) * | 2022-06-22 | 2023-09-01 | 中国科学院水生生物研究所 | 锰离子在防治水生病毒感染中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB933108A (en) * | 1960-02-03 | 1963-08-08 | Haessle Ab | Improvements in or relating to pharmaceutical iron preparations |
| DE3173906D1 (en) * | 1981-11-06 | 1986-04-03 | Kentaro Tanaka | An antianaemic agent and a process for producing the same |
| CN104431618A (zh) * | 2014-12-25 | 2015-03-25 | 常州海大生物饲料有限公司 | 一种防治异育银鲫腮出血的配合饲料及其使用方法 |
-
2021
- 2021-08-04 CN CN202110893972.8A patent/CN113559118B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113559118A (zh) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ochoa-Meza et al. | Silver nanoparticles enhance survival of white spot syndrome virus infected Penaeus vannamei shrimps by activation of its immunological system | |
| Li et al. | The immune response of white shrimp Litopenaeus vannamei and its susceptibility to Vibrio alginolyticus under low and high pH stress | |
| Cheng et al. | Effect of water temperature on the immune response of white shrimp Litopenaeus vannamei to Vibrio alginolyticus | |
| Yoganandhan et al. | Biochemical, physiological and hematological changes in white spot syndrome virus-infected shrimp, Penaeus indicus | |
| Lin et al. | White shrimp Litopenaeus vannamei that had received the hot-water extract of Spirulina platensis showed earlier recovery in immunity and up-regulation of gene expressions after pH stress | |
| CN113559118B (zh) | 亚铁离子在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用 | |
| Rodríguez-Ramos et al. | Effects of Echerichia coli lipopolysaccharides and dissolved ammonia on immune response in southern white shrimp Litopenaeus schmitti | |
| CN109602880A (zh) | 一种抗石斑鱼虹彩病毒的中药组合物及其应用 | |
| CN111035631B (zh) | 乳酸钙在制备防治鲤春病毒血症病毒感染的药物中的应用 | |
| CN105031128B (zh) | 预防或治疗水产养殖动物体外寄生虫的中药组合物及其制备方法和应用 | |
| Chen et al. | Research advances in the structure, function, and regulation of the gill barrier in teleost fish | |
| CN109602779B (zh) | 一种中药组合物及其在制备防治石斑鱼虹彩病毒病药物中的应用 | |
| JP4052534B2 (ja) | 魚介類用薬剤及び飼料 | |
| JPH0242443B2 (zh) | ||
| CN113201505A (zh) | 一株具备跨种裂解能力的溶藻弧菌噬菌体、其噬菌体组合物及其应用 | |
| CN108077331A (zh) | 一种水产养殖用的综合解毒液的制备方法及其应用 | |
| CN111676197A (zh) | 一株哈维氏弧菌噬菌体、其噬菌体组合物及其应用 | |
| CN112336745A (zh) | 含铁物质在制备抑制登革热病毒传播的产品中的应用 | |
| CN108178254A (zh) | 一种用于水产养殖的净水、解毒粉剂及其制作工艺 | |
| CN107320481A (zh) | 单宁酸在杀灭和预防水产动物体外寄生虫中的应用 | |
| CN106727471A (zh) | 肌醇作为氟苯尼考增效剂的应用 | |
| CN103891636A (zh) | 一种鱼病防治的方法 | |
| CN111543357A (zh) | 一种防控石斑鱼寄生菲律宾蛭的方法 | |
| Raghu et al. | Effect of Bacillus coagulans and B. firmus incorporated probiotic diet on Superoxide dismutase activity and catalase activity in Penaeus monodon | |
| TWI744983B (zh) | 針對多巴脫羧酵素之雙股rna的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240129 Address after: Building 2, No. 4 Fushan 6th Road, Qianwu Town, Doumen District, Zhuhai City, Guangdong Province, 519170 Patentee after: GUANGDONG LIANKUN GROUP Co.,Ltd. Country or region after: China Patentee after: Zhuhai Yulai Yuwang Biotechnology Co.,Ltd. Address before: 430072 No. 7 South East Lake Road, Wuhan, Hubei, Wuchang Patentee before: Institute of Hydrobiology, Chinese Academy of Sciences Country or region before: China |